22 independently detected trends connected to this subject, with the latest coverage first.
This hub groups 22 separate news trends connected to Lilly, spanning June 23, 2026 through October 29, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 180 article observations and 164 source signals, led by Business, Health, Entertainment coverage. Use it to compare how individual events emerged, spread and changed over time.
Eli Lilly’s Q3 earnings lift stock to record high as obesity‑drug sales boost revenue guidance
5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Missouri Attorney General sends cease-and-desist letter to Eli Lilly over drug pricing policy.
Evangeline Lilly publicly says she quit Hollywood because fame never felt right, citing faith and a desire for a quieter life.
Epic teams up with Amazon Pharmacy, Eli Lilly, and Mark Cuban to launch a prescription drug pricing tool.
6 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
Foghorn Therapeutics slashes 40% of staff after Lilly aborts a cancer partnership, sending its shares sharply lower.
People with Type 2 diabetes lose up to 60 pounds on Lilly’s latest weight loss drug
8.8 million Indians have dementia, with early diagnosis crucial for a crucial step forward in treatment.
700,000 seniors start GLP-1 treatments under Medicare, with 70% on Eli Lilly drugs
7 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
6 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Lilly Wachowski launches queer studio Anarchists United while accusing Harry Potter fans of funding trans genocide
Eli Lilly's $2.88 billion bid for Merida Biosciences marks its 13th 2026 acquisition, swelling Massachusetts biotech staffing.
The UK has approved a new weight-loss pill, marking a significant shift in obesity treatment options.
Novo Nordisk faces intensifying competition from Eli Lilly in the global GLP-1 weight-loss market as its early industry lead faces significant pressure.
Eli Lilly's retatrutide shows promising results in weight loss trials, driving stock gains and regulatory anticipation
Peptides are gaining broad attention across regulatory, skincare, and investment sectors following recent FDA scrutiny and market analysis.
Lilly, Johnson & Johnson and AbbVie stocks reach unprecedented levels as investors shift from tech to healthcare.
Sangamo Therapeutics' bankruptcy filing and asset sale to Lilly and Astellas is making waves in the biotech industry.
Speculation swirls around a 79-year-old patient who received an experimental weight loss drug, with former President Trump as the suspected recipient.